The Scientist

» preclinical

Most Recent

image: The Trouble With Sex in Science

The Trouble With Sex in Science

By | August 9, 2016

Researchers argue for the consideration of hormones and sex chromosomes in preclinical experiments.

0 Comments

image: TS Picks: February 11, 2016

TS Picks: February 11, 2016

By | February 11, 2016

Reproducibility edition

0 Comments

image: In Situ Antibodies

In Situ Antibodies

By | February 2, 2016

Compared with systemic injections, localized antibody therapies may be more effective for some indications.

2 Comments

image: The Sounds of Silence

The Sounds of Silence

By | September 1, 2015

Science-based tinnitus therapeutics are finally coming into their own.

3 Comments

image: Organ-on-a-Chip Gets Big Pharma Boost

Organ-on-a-Chip Gets Big Pharma Boost

By | June 18, 2015

Johnson & Johnson agrees to use Emulate’s blood-clot device in three of its preclinical drug programs.

0 Comments

image: Ebola Vaccines Protect Monkeys

Ebola Vaccines Protect Monkeys

By | April 9, 2015

Two new Ebola vaccine candidates prove safe and effective against the virus in macaques, a study shows.

0 Comments

image: NIH to Close Sex Gap in Preclinical Research

NIH to Close Sex Gap in Preclinical Research

By | May 15, 2014

The funding agency will require grant applicants to address sex balance in all future cell and animal studies.

0 Comments

image: Opinion: Pairing Discovery with Regulatory Rigor

Opinion: Pairing Discovery with Regulatory Rigor

By | May 13, 2014

To move cell-based therapies into the clinic, academic researchers may benefit by consulting researchers outside of academia and the biopharma industry.

0 Comments

image: The Promise of Nanomedicine

The Promise of Nanomedicine

By | April 8, 2014

At AACR, scientists discuss the growing interest in nanotechnology and how it can be used to study, diagnose, and treat cancer.

0 Comments

image: Opinion: Translational Biotechnology

Opinion: Translational Biotechnology

By | February 17, 2014

Regulators must consider both the promise and potential pitfalls of new technologies when determining whether to move them into clinical trials.

0 Comments

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. How Plants Evolved Different Ways to Make Caffeine
  3. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

  4. Another DNA Vaccine for Zika Shows Promise
RayBiotech